Scarica l'app Stockscreener
10.92
6.12%
0.63
Dopo l'orario di chiusura:
10.86
-0.06
-0.55%
Precedente Chiudi:
$10.29
Aprire:
$10.54
Volume 24 ore:
547.47K
Relative Volume:
0.67
Capitalizzazione di mercato:
$698.45M
Reddito:
$262.60M
Utile/perdita netta:
$-80.80M
Rapporto P/E:
-8.9795
EPS:
-1.2161
Flusso di cassa netto:
$-275.70M
1 W Prestazione:
+0.28%
1M Prestazione:
-17.86%
6M Prestazione:
+40.90%
1 anno Prestazione:
+34.32%
Intervallo 1D:
$10.39
$11.00
Intervallo di 1 settimana:
$9.9628
$11.25
Portata 52W:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.92 | 658.16M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aug EndMonth: Is Arvinas Inc in a bullish channelMarket Growth Review & Weekly Breakout Watchlists - baoquankhu1.vn
ARVN PE Ratio & Valuation, Is ARVN Overvalued - Intellectia AI
H.C. Wainwright reiterates Arvinas stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Arvinas stock rating on trial data By Investing.com - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX) - The Globe and Mail
Arvinas’ chief medical officer Berkowitz sells $71k in shares By Investing.com - Investing.com South Africa
Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas’ chief medical officer Berkowitz sells $71k in shares - Investing.com UK
Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan
Tranche Update on Arvinas, Inc.'s Equity Buyback Plan announced on September 17, 2025. - marketscreener.com
Arvinas (ARVN): Citigroup Raises Price Target to $21.00 and Main - GuruFocus
Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
BTIG Analyst Raises Price Target for Arvinas (ARVN) to $16 | ARV - GuruFocus
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
ARVN Should I Buy - Intellectia AI
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 By Investing.com - Investing.com South Africa
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 - Investing.com India
BTIG raises Arvinas stock price target on positive trial data By Investing.com - Investing.com Australia
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
BTIG raises Arvinas stock price target on positive trial data - Investing.com
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas - TipRanks
Arvinas (ARVN) Reports Promising Phase 1 Trial Results for ARV-102 in Parkinson's Disease - GuruFocus
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data By Investing.com - Investing.com Australia
Arvinas, Inc. Reports Forward-Looking Statements and Updates on ARV-102 Neurodegenerative Disease Program – March 2026 - Minichart
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data - Investing.com
Arvinas (NASDAQ:ARVN) Trading Down 7.8%What's Next? - MarketBeat
Arvinas Reports Positive Phase 1 Data for ARV-102 - TipRanks
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days - The Manila Times
Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease - Stock Titan
Experimental Parkinson’s pill from Arvinas cuts key brain protein by 50% - Stock Titan
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days - Bitget
Arvinas shows market leadership with jump to 92 RS rating - MSN
Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares - Stock Titan
ARVN SEC FilingsArvinas 10-K, 10-Q, 8-K Forms - Stock Titan
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas calls for new approaches in neurodegenerative disease research - Traders Union
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Investor Mood: Can Arvinas Inc outperform in the next rally2026 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 7.8%What's Next? - MarketBeat
Arvinas to present ARV-102 Parkinson’s trial data at conference By Investing.com - Investing.com South Africa
Arvinas, Inc. (NASDAQ:ARVN) Q4 2025 earnings call transcript - MSN
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - The Manila Times
Arvinas, Inc. to Present Phase 1 Trial Data on ARV-102 for Parkinson’s Disease at AD/PD 2026 Conference - Quiver Quantitative
Arvinas to present ARV-102 Parkinson’s trial data at conference - Investing.com
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 - GlobeNewswire
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):